SILVER SPRING, Md. and SINGAPORE, Singapore, Aug. 24, 2012 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB: NVLX), an international biotechnology provider of cell and gene therapy solutions, announced today that Dr. Robert F. Ryan, President and CEO of Nuvilex, is in Asia and Singapore this week for numerous meetings with the Executives and staff of its wholly-owned subsidiary, Austrianova Singapore (ASPL), as well as other companies and groups in the region. In addition to specific work with Dr. Walter Gunzburg, ASPL Chairman, and Dr. Brian Salmons, President and CEO of ASPL, and the other ASPL executives and staff regarding Nuvilex's pancreatic cancer treatment, other avenues for the development of Nuvilex and its Cell-in-a-Box® live cell encapsulation technology have been discussed. Since his arrival Tuesday, management has been working closely together discussing possible partnerships with other entities regarding the use of the cell encapsulation technology, a major combined effort for the company. Meetings in Beijing and Singapore have included discussions with previous partners of ASPL regarding potential business opportunities. In commenting upon his effort in Singapore, Dr. Ryan stated, "These meetings, especially those with the staff of the recently-acquired subsidiary, Austrianova Singapore, have been both timely and crucial as Nuvilex progresses in the biotechnology arena. It's important to establish and solidify the link between our two companies and staff and to ensure a seamless integration of ASPL into Nuvilex for the benefit of all of our staff and future. This is turning out to be a fantastic experience and I believe much will be gained from my visit." About Nuvilex Nuvilex, Inc. (OTCQB: NVLX) is an international biotechnology provider of live therapeutically valuable, encapsulated cells and services for research and medicine. A great deal of work is ongoing to move Nuvilex and our Austrianova Singapore subsidiary forward. More information is anticipated to be coming regarding Dr. Ryan's ongoing travel for the Company. Our company's clinical offerings will include cancer, diabetes and other treatments using the company's cell and gene therapy expertise and live-cell encapsulation technology. The Nuvilex, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13494 Safe Harbor Statement This press release contains forward-looking statements described within the 1995 Private Securities Litigation Reform Act involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.
CONTACT: Investor Relations Contact: Marlin Molinaro Marmel Communications, LLC Ph: (702) 434-8692 firstname.lastname@example.org